Relationships of emerging biomarkers of cancer cachexia with quality of life, appetite, and cachexia.
Anorexia
Appetite
Biomarkers
Cachexia
Quality of life
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
30
10
2023
accepted:
05
05
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
Quality of life (QoL), appetite, cachexia, and biomarkers [albumin, hemoglobin (Hb), neutrophils, lymphocytes, platelets, C-reactive protein (CRP), tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6), interleukin 8 (IL-8), C-X-C motif chemokine ligand 5 (CXCL5) and citrullinated histoneH3 (H3Cit)] were compared for 40 cases with advanced cancer and 40 healthy controls. Baseline differences and significant relationships were explored for biomarkers with QoL, appetite, and cachexia. In a prospective case-control, age and sex matched study, the European Organisation for the Research and Treatment of Cancer Quality of Life-C30 questionnaire (EORTC-QLQ-C30) for QoL, the Functional Assessment of Anorexia and Cachexia Therapy assessment (FAACT A/CS-12) for appetite, and a five-factor cachexia assessment tool for cachexia assessment were performed. Routine hematological measurements and blood chemistry analyses together with ELISA procedures and a Multiplex® bead array platform, were used for biomarker analysis. Descriptive statistics and regression analyses were undertaken. P < 0.05 defined statistical significance. Global health status (QL-G), functional scales (QL-FS), and symptom scales (QL-SS) differed for cases and controls (p < 0.01). In cases, differences were observed for QL-G (p < 0.01), QL-FS (p < 0.01), and QL-SS (p = 0.01) compared to standardized references values. FAACT A/CS-12 scores differed significantly between cases and controls (p < 0.01) and 30% of cases scored "poor" appetites. Cachexia was present in 60% of cases. Albumin, lymphocytes, platelets, Hb, platelet to lymphocyte ratio (PLR), systemic immune-inflammation index (SII), CRP, TNFα, all at p < 0.01, neutrophil to lymphocyte ratio (NLR) (p = 0.02), IL-6 (p < 0.04), and IL-8 (p = 0.02) differed significantly between cases and controls. No difference was found for CXCL5 or H3Cit. Albumin NLR, Hb, PLR, SII, TNFα, IL-8, and CRP showed significant relationships with all aspects of QoL. QL-FS was significantly related to CXCL5 (p = 0.04), significant relationships with FAACT A/CS-12 included: NLR (p = 0.002), Hb (p < 0.001), and PLR (p < 0.01). NLR, PLR, SII, TNFα, IL-6, IL-8, and CRP correlated positively to cachexia and albumin while Hb and lymphocyte count correlated negatively to cachexia. CXCL5 and H3Cit were not reliable biomarkers for cancer cachexia, nor significantly related to QoL, appetite or cachexia. Albumin, NLR, Hb, PLR, SII, TNFα, IL-8, and CRP were reliable indicators of QoL, appetite, and cachexia. Future research should include other novel biomarkers namely growth differentiation factor-15 (GDF-15), fibroblast growth factor 21 (FGF-21), fractakline, interferon gamma (IFN-y), IL-16, macrophage colony stimulating factor (M-CSF), and macrophage procoagulant-inducing factor (MPIF).
Identifiants
pubmed: 38744744
doi: 10.1007/s00520-024-08549-5
pii: 10.1007/s00520-024-08549-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
349Informations de copyright
© 2024. The Author(s).
Références
Ryan AM, Power DG, Daly L, Cushen SJ, Ní Bhuachalla E, Prado CM (2016) Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc 75(2):199–211. https://doi.org/10.1017/S002966511500419X
doi: 10.1017/S002966511500419X
pubmed: 26786393
Srdic D, Plestina S, Sverko-Peternac A, Nikolac N, Simundic AM, Samarzija M (2016) Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer—chemotherapy toxicity and prognostic value. Support Care Cancer 24(11):4495–4502. https://doi.org/10.1007/s00520-016-3287-y
doi: 10.1007/s00520-016-3287-y
pubmed: 27236439
Argilés JM, Busquets S, López-Soriano FJ (2019) Cancer cachexia, a clinical challenge. Curr Opin Oncol 31(4):286–290. https://doi.org/10.1097/CCO.0000000000000517
doi: 10.1097/CCO.0000000000000517
pubmed: 30893144
Abraham M, Kordatou Z, Barriuso J, Lamarca A, Weaver JM, Cipriano C, Papaxoinis G, Backen A, Mansoor W (2019) Early recognition of anorexia through patient-generated assessment predicts survival in patients with oesophagogastric cancer. PLoS ONE 14(11):1–18. https://doi.org/10.1371/journal.pone.0224540
doi: 10.1371/journal.pone.0224540
Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE (2019) Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition 67–68:1–11. https://doi.org/10.1016/j.nut.2019.06.020
doi: 10.1016/j.nut.2019.06.020
Blauwhoff-Buskermolen S, Ruijgrok C, Ostelo RW, de Vet HCW, Verheul HMW, van der Schueren MAE, Langius JAE (2016) The assessment of anorexia in patients with cancer: cut-off values for the FAACT–A/CS and the VAS for appetite. Support Care Cancer 24(2):661–666. https://doi.org/10.1007/s00520-015-2826-2
doi: 10.1007/s00520-015-2826-2
pubmed: 26160463
Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tcheckmedyian NS, Von Roenn J, Leslier WT et al (2000) Re-validation and shortening of the functional assessment of anorexia/cachexia therapy (FAACT) questionnaire. Qual Life Res 9(10):1137–1146. https://doi.org/10.1023/A:1016670403148
doi: 10.1023/A:1016670403148
pubmed: 11401046
Narasimhan A, Shahda S, Kays JK, Perkins SM, Cheng L, Schloss KNH, Schloss D et al (2020) Identification of potential serum protein biomarkers and pathways for pancreatic cancer cachexia using an aptamer-based discovery platform. Cancers 12(12):1–23. https://doi.org/10.3390/cancers12123787
doi: 10.3390/cancers12123787
Davis M, Yavuzsen T, Kirkova J, Walsk D, Karafa M, LeGrand S, Lagman R (2009) Validation of a simplified anorexia questionnaire. J Pain Symptom Manage 38(5):691–697. https://doi.org/10.1016/j.jpainsymman.2009.03.012
doi: 10.1016/j.jpainsymman.2009.03.012
pubmed: 19896572
Zhou T, Wang B, Liu H, Yang K, Thapa S, Zhang H, Li L, Yu S (2018) Development and validation of a clinically applicable score to classify cachexia stages in advanced cancer patients. J Cachexia Sarcopenia Muscle 9(2):306–314. https://doi.org/10.1002/jcsm.12275
doi: 10.1002/jcsm.12275
pubmed: 29372594
pmcid: 5879986
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N, Filiberti A, Fletchner H et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://doi.org/10.1093/jnci/85.5.365
doi: 10.1093/jnci/85.5.365
pubmed: 8433390
McDonald JJ, Fallon MT, Laird BJA (2019) Meaningful measures in cancer cachexia: implications for practice and research. Curr Opin Support Palliat Care 13(4):323–327. https://doi.org/10.1097/SPC.0000000000000472
doi: 10.1097/SPC.0000000000000472
pubmed: 31599817
Kadakia KC, Hamilton-Reeves JM, Baracos VE (2023) Current therapeutic targets in cancer cachexia: a pathophysiologic approach. Am Soc Clin Oncol Educ B 43. https://doi.org/10.1200/edbk_389942
Baracos VE, Martin L, Korc M, Guttridge CD, Fearon KCH (2018) Cancer-associated cachexia. Nat Rev Clin Oncol 4:1–18. https://doi.org/10.1038/nrdp.2017.105
doi: 10.1038/nrdp.2017.105
Roca H, Jones JD, Purica MC, Weidner S, Koh AJ, Kuo R, Wilkinson JE, Wang Y et al (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128(1):248–266. https://doi.org/10.1172/JCI92466
doi: 10.1172/JCI92466
pubmed: 29202471
Zhang W, Wang H, Sun M, Deng X, Wu X, Ma Y, Li M, Shuoa S, You Q, Miao L (2020) CXCL5 / CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun 40:69–80. https://doi.org/10.1002/cac2.12010
doi: 10.1002/cac2.12010
Wu K, Yu S, Liu Q, Bai X, Zheng X, Wu K (2017) The clinical significance of CXCL5 in non-small cell lung cancer. Onco Targets Ther 10:5561–5573. https://doi.org/10.2147/OTT.S148772
doi: 10.2147/OTT.S148772
pubmed: 29200871
pmcid: 5702175
Thålin C, Lundstrom S, Seignez C, Daleskog M, Lundstrom A, Henriksson P, Helleday T, Phillipson M, Wallen H, Demers M (2018) Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer. PLoS ONE 13(1):1–17. https://doi.org/10.1371/journal.pone.0191231
doi: 10.1371/journal.pone.0191231
Lipshitz M, Visser J, Anderson R, Nel DG, Smit T, Steel HC, Rapoport BL (2023) Emerging markers of cancer cachexia and their relationship to sarcopenia. J Cancer Res Clin Oncol 149(19):17511–17527. https://doi.org/10.1007/s00432-023-05465-9
doi: 10.1007/s00432-023-05465-9
pubmed: 37906352
pmcid: 10657295
Citrullinated Histone H3 (Clone 11D3) ELISA Kit. no. 501620 (2020) Cayman chemical company, 1180 E Ellsworth Road, Ann Arbor MI, USA. https://www.caymanchem.com/product/501620/citrullinated-histone-h3-(clone-11d3)-elisa-kit . Accessed 10 Jun 2021
Mystakidou K, Tsilika E, Parpa E, Kalaidopoulou O, Smyrniotis V, Vlahos L (2001) The EORTC core quality of life questionnaire (QLQ-C30, version 3.0) In terminally ill cancer patients under palliative care: validity and reliability in a hellenic sample. Int J Cancer 94(1):135–139. https://doi.org/10.1002/ijc.1439
doi: 10.1002/ijc.1439
Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ- C30 scoring manual. European organisation for research and treatment of cancer, 3rd ed. Brussels, Belgium
Scott NW, Fayers PM, Aaronson NK, Bottomly A, de Graeff A, Groenvold M, Grundy C, Koller M, Petersen M, Sprangers MA. MAG, EORTC Quality of Life Group (2008) EORTC QLQ- C30 reference values manual. 2nd edn, EORTC Quality of Life Group. Brussels, Belgium. https://groups.eortc.be/qol/downloads/reference_values_manual2008.pdf . Accessed 26 Jun 2021
Franceschini JP, Jamnik S, Santoro IL (2020) Role that anorexia and weight loss play in patients with stage iv lung cancer. J Bras Pneumol 46(4):1–6. https://doi.org/10.36416/1806-3756/e20190420
doi: 10.36416/1806-3756/e20190420
Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saraconi V, Barone C, Plastoni F et al (2017) Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. Oncotarget 8(45):79884–79896. https://doi.org/10.18632/oncotarget.20168
doi: 10.18632/oncotarget.20168
pubmed: 29108370
pmcid: 5668103
Mondello P, Lacquaniti A, Mondello S, Bolignano D, Pitni V, Aloisi C, Beumi M (2014) Emerging markers of cachexia predict survival in cancer patients. BMC Cancer 14(1):1–10. https://doi.org/10.1186/1471-2407-14-828
doi: 10.1186/1471-2407-14-828
Ezeoke CC, Morley JE (2015) Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle 6(4):287–302. https://doi.org/10.1002/jcsm.12059
doi: 10.1002/jcsm.12059
pubmed: 26675762
pmcid: 4670736
Sundstrøm S, Bremnes RM, Brunsvig P, Aasebø U, Kaasa S (2006) Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? J Thorac Oncol 1(8):816–824. https://doi.org/10.1016/s1556-0864(15)30411-1
doi: 10.1016/s1556-0864(15)30411-1
pubmed: 17409965
Pasetto LM, Falci C, Compostella A, Sinigaglia G, Rossi E, Monfardini E (2007) Quality of life in elderly cancer patients. Eur J Cancer 43(10):1508–1513. https://doi.org/10.1016/j.ejca.2006.11.023
doi: 10.1016/j.ejca.2006.11.023
pubmed: 17292603
Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, Strasser F et al (2015) Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 33(1):90–99. https://doi.org/10.1200/JCO.2014.56.1894
doi: 10.1200/JCO.2014.56.1894
pubmed: 25422490
Daly L, Dolan R, Power D, Ni Bhuachalla EN, Sim W, Fallon M, Cushen S et al (2020) The relationship between the BMI-adjusted weight loss grading system and quality of life in patients with incurable cancer. J Cachexia Sarcopenia Muscle 11(1):160–168. https://doi.org/10.1002/jcsm.12499
doi: 10.1002/jcsm.12499
pubmed: 31692296
Bullock AF, Greenley SL, McKenzie GAG, Paton LW, Johnson MJ (2020) Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis. Eur J Clin Nutr 74(11):1519–1535. https://doi.org/10.1038/s41430-020-0629-0
doi: 10.1038/s41430-020-0629-0
pubmed: 32366995
pmcid: 7606134
Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116(7):11–26. https://doi.org/10.1016/j.amjmed.2003.12.008
doi: 10.1016/j.amjmed.2003.12.008
Paczek S, Łukaszewicz-Zajac M, Gryko M, Mroczko P, Kulczyńska-Przybik A, Mroczko B (2020) CXCL-8 in preoperative colorectal cancer patients: significance for diagnosis and cancer progression. Int J Mol Sci 21(6):1–13. https://doi.org/10.3390/ijms21062040
doi: 10.3390/ijms21062040
Lim JB, Chung HW (2015) Serum ENA78/CXCL5, SDF-1/CXCL12, and their combinations as potential biomarkers for prediction of the presence and distant metastasis of primary gastric cancer. Cytokine 73(1):16–22. https://doi.org/10.1016/j.cyto.2015.01.010
doi: 10.1016/j.cyto.2015.01.010
pubmed: 25689618
Mantovani G, Maccio A, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Madeddu DA (2000) Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78(10):554–556. https://doi.org/10.1007/s001090000137
doi: 10.1007/s001090000137
pubmed: 11199328
Guo ZQ, Yu JM, Li W, Fu ZM, Lin Y, Shi YY, Hu W, Ba Y, Li SY et al (2019) Survey and analysis of the nutritional status in hospitalized patients with malignant gastric tumors and its influence on the quality of life. Support Care Cancer 28(1):373–380. https://doi.org/10.1007/s00520-019-04803-3
doi: 10.1007/s00520-019-04803-3
pubmed: 31049672
pmcid: 6882767
Wang B, Thapa S, Zhou T, Liu H, Li L, Peng G, Yu S (2020) Cancer-related fatigue and biochemical parameters among cancer patients with different stages of sarcopenia. Support Care Cancer 28(2):581–588. https://doi.org/10.1007/s00520-019-04717-0
doi: 10.1007/s00520-019-04717-0
pubmed: 31102055
Fiala O, Pesek M, Finek J, Racek J, Minarik M, Benesova L, Bortlicek Z et al (2016) Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. Neoplasma 63(3):471–476. https://doi.org/10.4149/318_151001N512
doi: 10.4149/318_151001N512
pubmed: 26952513
Tan T, Ong WS, Rajasekaran T, Koo KN, Chan LL, Poon D, Chowdury AR, Krishna L, Kanesvaran R (2016) Identification of comprehensive geriatric assessment based risk factors for malnutrition in elderly Asian cancer patients. PLoS ONE 11(5):1–12. https://doi.org/10.1371/journal.pone.0156008
doi: 10.1371/journal.pone.0156008
Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N, Jenkinson C et al (2002) The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 86(8):1243–1249. https://doi.org/10.1038/sj.bjc.6600247
doi: 10.1038/sj.bjc.6600247
pubmed: 11953880
pmcid: 2375336
Wu M, Lian XJ, Jia JM, Cao WT, Yan N, Xin YM, Liu ZR et al (2019) The role of the patient-generated subjective global assessment (PG-SGA) and biochemical markers in predicting anemia patients with cancer. Support Care Cancer 27(4):1443–1448. https://doi.org/10.1007/s00520-018-4462-0
doi: 10.1007/s00520-018-4462-0
pubmed: 30206725
Takeda T, Sasaki T, Suzumori C, Mie T, Furukawa T, Yamada Y, Kasuga A et al (2021) The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Int J Clin Oncol 26(7):1293–1303. https://doi.org/10.1007/s10147-021-01912-0
doi: 10.1007/s10147-021-01912-0
pubmed: 33791917
de Cordeiro LDAF, Silva TH, de Oliveira LC, Neto JFN (2020) Systemic inflammation and nutritional status in patients on palliative cancer care: a systematic review of observational studies. Am J Hosp Palliat Med 37(7):565–571. https://doi.org/10.1177/1049909119886833
doi: 10.1177/1049909119886833
Kim EY, Kim YS, Seo J, Park I, Ahn AK (2016) The relationship between sarcopenia and systemic inflammatory response for cancer cachexia in small cell lung cancer. PLoS ONE 11(8):1–10. https://doi.org/10.1371/journal.pone.0161125
doi: 10.1371/journal.pone.0161125
Li L, Chan SL, Mo F, Hui EP, Koh J, Chan AK, Nls Tang, Chu CM, Hui J et al (2019) Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients. Qual Life Res 28(9):2597–2607. https://doi.org/10.1007/s11136-019-02190-0
doi: 10.1007/s11136-019-02190-0
pubmed: 31037590
Paulsen Ø, Laird B, Aass N, Lea T, Fayers KS, Klepstad P (2017) The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer. PLoS ONE 12(5):1–16. https://doi.org/10.6084/m9.figshare.4981502
doi: 10.6084/m9.figshare.4981502